Compugen - CGEN Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGEN shares.
View CGEN analyst ratings or view top-rated stocks.

6 brokers have issued 12 month price targets for Compugen's stock. Their CGEN share price forecasts range from $2.00 to $13.00. On average, they anticipate the company's share price to reach $6.20 in the next year. This suggests a possible upside of 771.2% from the stock's current price.
View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts.

Compugen's stock was trading at $0.7157 on January 1st, 2023. Since then, CGEN stock has decreased by 0.6% and is now trading at $0.7117.
View the best growth stocks for 2023 here.

Compugen saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 2,090,000 shares, an increase of 14.2% from the February 13th total of 1,830,000 shares. Based on an average trading volume of 576,100 shares, the days-to-cover ratio is presently 3.6 days. Approximately 2.6% of the shares of the company are sold short.
View Compugen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our CGEN earnings forecast.

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings results on Monday, February, 27th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The biotechnology company earned $7.50 million during the quarter. During the same period in the prior year, the firm posted ($0.10) earnings per share.

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Compugen's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (2.78%), Taylor Frigon Capital Management LLC (1.64%), Renaissance Technologies LLC (1.47%), Macquarie Group Ltd. (0.98%), Two Sigma Investments LP (0.96%) and Morgan Stanley (0.85%).

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CGEN stock can currently be purchased for approximately $0.71.

Compugen (NASDAQ:CGEN) has a market capitalization of $61.65 million and generates $7.50 million in revenue each year. The biotechnology company earns $-33,690,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The official website for the company is www.cgen.com. The biotechnology company can be reached via phone at (723) 765-8585, via email at ir@cgen.com, or via fax at 972-3765-8555.